{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:28:08Z","timestamp":1779222488669,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-024-03633-3","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:01:52Z","timestamp":1726747312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China"],"prefix":"10.1186","volume":"22","author":[{"given":"Yanhua","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengling","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongshun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiping","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zizheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuerui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"3633_CR1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023."},{"issue":"Suppl. 1","key":"3633_CR2","first-page":"S15","volume":"18","author":"A Tr\u00e9bucq","year":"2014","unstructured":"Tr\u00e9bucq A, Schwoebel V, Kuaban C, et al. Expanding shortened MDR-TB treatment: the West African experience. Int J Tuberc Lung Dis. 2014;18(Suppl. 1):S15.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"3633_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001300","volume":"9","author":"SD Ahuja","year":"2012","unstructured":"Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8): e1001300.","journal-title":"PLoS Med"},{"issue":"11","key":"3633_CR4","first-page":"1382","volume":"8","author":"E Nathanson","year":"2004","unstructured":"Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8(11):1382\u20134.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"3633_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063057","volume":"8","author":"K Shean","year":"2013","unstructured":"Shean K, Streicher E, Pieterson E, Symons G, van Zyl SR, Theron G, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS ONE. 2013;8(5): e63057.","journal-title":"PLoS ONE"},{"issue":"1","key":"3633_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","volume":"42","author":"D Falzon","year":"2013","unstructured":"Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156\u201368.","journal-title":"Eur Respir J"},{"key":"3633_CR7","first-page":"2022","volume-title":"update","author":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. update. Geneva, Switzerland: World Health Organization; 2022. p. 2022."},{"key":"3633_CR8","volume-title":"Technical Guidelines for tuberculosis Prevention and Control in China","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Chen M. Technical Guidelines for tuberculosis Prevention and Control in China. Beijing: People\u2019s Medical Publishing House; 2021."},{"issue":"2","key":"3633_CR9","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20210384","volume":"48","author":"H Hatami","year":"2022","unstructured":"Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2): e20210384.","journal-title":"J Bras Pneumol"},{"key":"3633_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","volume":"111","author":"L Fu","year":"2021","unstructured":"Fu L, Weng T, Sun F, Zhang P, Li H, Li Y, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;111:138\u201347.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"3633_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"issue":"8","key":"3633_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"3633_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/cid\/ciz915","volume":"71","author":"Y Du","year":"2020","unstructured":"Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H, et al. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clin Infect Dis. 2020;71(4):1047\u201354.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3633_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","volume":"45","author":"S Tang","year":"2015","unstructured":"Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161\u201370.","journal-title":"Eur Respir J"},{"issue":"2","key":"3633_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"BT Nyang'wa","year":"2024","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B\u20133, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117\u201328.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3633_CR16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3201\/eid2505.181823","volume":"25","author":"L Mbuagbaw","year":"2019","unstructured":"Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2019;25(5):936\u201343.","journal-title":"Emerg Infect Dis"},{"key":"3633_CR17","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.2147\/IDR.S419996","volume":"16","author":"H Ke","year":"2023","unstructured":"Ke H, Gui X, Sun W, Zhang S, Yang Y, Zhang Z, et al. The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant\/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China. Infect Drug Resist. 2023;16:5055\u201364.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"3633_CR18","doi-asserted-by":"publisher","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","volume":"49","author":"L Guglielmetti","year":"2017","unstructured":"Guglielmetti L, Jaspard M, Le D\u00fb D, Lach\u00e2tre M, Marigot-Outtandy D, Bernard C, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799.","journal-title":"Eur Respir J"},{"issue":"4","key":"3633_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cmi.2020.06.004","volume":"27","author":"M Gao","year":"2021","unstructured":"Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597\u2013602.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"3633_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/cid\/ciab304","volume":"73","author":"H Hwang","year":"2021","unstructured":"Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid. Clin Infect Dis. 2021;73(8):1362\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3633_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/cid\/ciad312","volume":"77","author":"CA Haley","year":"2023","unstructured":"Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, et al. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clin Infect Dis. 2023;77(7):1053\u201362.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3633_CR22","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/cid\/ciac528","volume":"76","author":"C Padmapriyadarsini","year":"2022","unstructured":"Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022;76(3):e938\u201346.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3633_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/cid\/ciu786","volume":"60","author":"L Guglielmetti","year":"2015","unstructured":"Guglielmetti L, Le D\u00fb D, Jachym M, Henry B, Martin D, Caumes E, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60(2):188\u201394.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3633_CR24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/cid\/ciy727","volume":"68","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis. 2019;68(9):1522\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3633_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4269\/ajtmh.2006.75.1027","volume":"75","author":"V Kawai","year":"2006","unstructured":"Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, Huaroto L, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg. 2006;75(6):1027\u201333.","journal-title":"Am J Trop Med Hyg"}],"updated-by":[{"DOI":"10.1186\/s12916-024-03694-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000}}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03633-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T06:03:56Z","timestamp":1729058636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03633-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03633-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12916-024-03694-4","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12916-024-03694-4","URL":"https:\/\/doi.org\/10.1186\/s12916-024-03694-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Beijing Chest Hospital, Capital Medical University, ID: (2019) Clinical Review (86).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"401"}}